Horizon Pharma Soars On Q4 Beat, Guidance Raise

By | February 27, 2015

Scalper1 News

Specialty drugmaker Horizon Pharma (HZNP) beat analysts’ Q4 expectations and raised its 2015 guidance Friday, sending its stock up 10% to a new high. Horizon’s revenue in the quarter more than tripled to $103.8 million, about $8 million above analysts’ consensus, according to Thomson Reuters. Excluding one-time items, the firm made 27 cents a share, reversing a year-earlier loss and beating estimates by 5 cents. For the year, sales jumped 300% to Scalper1 News

Scalper1 News